The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care

Michael A. Postow, MD
Published Online:6:08 PM, Mon September 18, 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the results of the COMBI-AD study and the CheckMate-238 study will impact the care of patients with melanoma.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.